Research literacy

Understand peptides.
Question the claims.
Stay informed.

A UK space for clear writing about peptide research topics — what the science actually says, what “research only” really means, and why grey-market products deserve honest scrutiny.

Evidence-ledEducation firstIndependent writingResearch framing
Peptides Kent research community
UKResearch literacy hub
Be straight with people

Grey market is still grey market.

Helpful communities tell the truth even when it is uncomfortable. Marketing language is not regulation.

MHRA wording ≠ licensed medicine

A seller can say they “follow MHRA guidelines”, call themselves a research company, or paste disclaimers on a site. That does not mean the product is an authorised UK medicine, that every batch is inspected like a pharmacy product, or that purity matches the label.

“Research only” is a framing

“Not for human consumption” and “research chemical” labels are common in this space. Take them seriously. They also do not magically guarantee quality, sterility, or that the vial contains what the listing claims.

Anecdotes are not trials

Forums, chats, and before/after stories are not controlled evidence. Useful for spotting questions to ask — dangerous if treated as proof of safety or effect.

Community > hype

We would rather help people read certificates, spot weak claims, and talk honestly than pretend every catalogue is pharmaceutical-grade. Curiosity is welcome. Wishful thinking is not.

This website provides general information for educational discussion. It is not medical advice, not a prescription service, and not a claim that any compound is safe or appropriate for any person or purpose.
Evidence reviews

What the evidence actually shows.

Independent reviews of compounds circulating on the UK grey market. Open a review for the full evidence page.

Cagrilintide

A late-stage drug candidate mostly studied as half of a combination — sold alone on the grey market in ways the trial programme largely has not tested.

Evidence review

GHK-Cu

Strong mechanistic data, thin human trial data, and an injectable form that has barely been studied in people.

Evidence review

Ipamorelin

A genuine pharmacological compound taken into human trials — then stopped. That decision tells you more than most of what is written about it since.

Evidence review

KPV

Coherent anti-inflammatory rationale and interesting preclinical literature — with virtually no human clinical trial evidence.

Evidence review

Melanotan I

The only tanning-peptide relative with an approved medicine behind it — for a rare disorder, as a hospital implant, not an online vial.

Evidence review

Melanotan II

Clearest regulatory position and sharpest safety signal on this site. Never approved; MHRA has warned repeatedly.

Evidence review

MOTS-c

A real mitochondrial biology discovery — and one of the least clinically tested compounds sold on the grey market.

Evidence review

NAD+

Essential to metabolism. Whether injecting or infusing it produces measurable clinical benefit is a far weaker claim than the marketing suggests.

Evidence review

Peptide blends

Sold under names like Wolverine, KLOW and Glow. Combining compounds that lack evidence does not create evidence for the blend.

Evidence review

Retatrutide

Largest weight-loss results in randomised trials — and not approved anywhere, so every circulating vial came from somewhere other than a licensed manufacturer.

Evidence review

SS-31 (Elamipretide)

Unusual here: a large clinical programme with one narrow approval and several failures — more informative than no data.

Evidence review

Tesamorelin

Genuine phase 3 evidence for visceral fat in HIV-associated lipodystrophy — a narrow indication, not what the grey market usually sells it for.

Evidence review

Tirzepatide

Licensed UK medicine with strong trials — which is exactly why grey-market and counterfeit supply is such a serious problem.

Evidence review
Blog

From the blog.

Use Copy link on an article to share that post only.

FAQ

Straight answers.

What does “grey market” mean for peptides?

It means products are often sold outside the normal licensed-medicine pathway. Labels, websites, or “research company” branding do not equal MHRA approval as a medicine, and quality can vary between sellers and batches.

If a company says it follows MHRA guidelines, is that enough?

No. Claiming to follow guidelines is not the same as holding the right authorisations, undergoing the inspections expected of licensed medicines, or proving every batch is what the label says. Stay sceptical and read primary evidence.

How is this site organised?

The research pages (this page and the compound reviews) are educational and kept separate from ordering. Questions? Use the Contact page.